More articles from MTA I: Radiopharmaceutical Therapy Posters

You have access
Is peptide receptor radionuclide therapy an option after liver transplantation in progressive metastatic neuroendocrine tumors?
Harshad Kulkarni, Daniel Kaemmerer, Dieter Hoersch, Merten Hommann and Richard Baum

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1177;
You have access
Tumor response assessment to treatment with [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in patients with gastroenteropancreatic neuroendocrine tumors: Differential response of bone versus soft tissue lesions
Esther van Vliet, John Hermans, Maria de Ridder, Jaap Teunissen, Boen liong Kam, Ronald de Krijger, Eric Krenning and Dik Kwekkeboom

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1181;
You have access
The influence on rat’s thyroid weight and function by applying nicotinamide with 131I
Jin Jianhua, Li Xiaomin, Niu Rong, Fu Songhai, Liu Ye and Li Sijin

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1212;
You have access
Radiation dosimetry of glass versus resin Y-90 microsphere radioembolization in patients with colorectal liver metastases
Vamsi Kunam, Sankaran Shrikanthan and Shyam Srinivas

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1203;
You have access
Accurate assessment of long-term nephrotoxicity after therapy with 177Lu-octreotate
Amir Sabet, Khaled Ezziddin, Karl Reichmann, Hojjat Ahmadzadehfar, Torjan Haslerud, Stefan Guhlke, Hans Jürgen Biersack and Samer Ezziddin

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1186;
You have access
Therapeutic response assessment in radio-immunotherapy: Comparison of metabolic (PERCIST) and anatomic (RECIST) tumor response criteria
Jure Murgic, Yuni Dewaraja, Ka kit Wong, Mark Kaminski and Anca Avram

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1197;
You have access
Molecular radiotherapy with 131 iodine metaiodobenzylguanidine in malignant pheochromocytomas/paragangliomas - Are we making a difference?
R. Chakravartty, Gillian Vivian, B. Corcoran, S. Al-Shahwan, L. Devlin, Muriel Buxton-Thomas and N. Mulholland

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1191;
You have access
Pathomechanism and identification of new therapeutic strategies in radiation induced nephropathy after Lu-177-DOTATATE therapy
Harun Ilhan, Hao Wang, Franz Gildehaus, Carmen Wängler, Tanja Herrler, Heidrun Zankl, Peter Bartenstein, Marcus Hacker and Alexander Haug

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1187;
You have access
Can peptide receptor radionuclide therapy be safely applied in florid bone metastases of gastroenteropancreatic neuroendocrine tumours?
Amir Sabet, Charlotte Yong-Hing, Khaled Ezziddin, Hojjat Ahmadzadehfar, Stefan Guhlke, Frank Gruenwald, Hans Jürgen Biersack and Samer Ezziddin

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1183;
You have access
Using F-18-BPA imaging to evaluate recurrent head-and-neck cancer treated with boron neutron capture therapy
Shyh-Jen Wang, Ling-Wei Wang, Bang-Hung Yang, Ko-Han Lin and Fong-In Chou

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1196;

Main menu

User menu

Search

More articles from MTA I: Radiopharmaceutical Therapy Posters

Pages